sivelestat

Small moleculeexperimental

Sivelestat is an inhibitor of human neutrophil elastase. — Wikipedia

Clinical trial activity

15 trials · 19 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
3

Earliest trial started Aug 1, 2001 (NCT00036062)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)[O-])cc1.O.O.O.O.[Na+]
Mol. weight
528.51 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • glycine, n-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-
  • n-(2-(4-(2,2-dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid
  • ono 5046
  • ono-5046
  • ono-5046
  • ono-5046
  • ono-5046
  • ono-5046.na
  • ono-5046.na
  • ono-ei-600
  • sivelestat
  • sivelestat
  • sivelestat
  • sivelestat
  • sivelestat
  • sivelestat
  • sivelestat
  • sivelestat
  • sivelestat sodium
  • sivelestat sodium
  • sivelestat sodium hydrate
  • sivelestat sodium hydrate
  • sivelstat

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07214103Phase 2Mar 1, 2026University of Strasbourg
NCT07196605N/AOct 1, 2025Capital Medical University
NCT07156656Phase 4Sep 1, 2025Anhui Medical University, Changhai Hospital, Fudan University, Fujian Provincial Hospital, Jiao Tong University, Shantou University, The University of Hong Kong
NCT06387823N/AApr 15, 2024Chinese Academy of Medical Sciences, Government of China, Peking University
NCT05874700N/AMay 31, 2023Capital Medical University
NCT05697016N/AJan 31, 2023Capital Medical University
NCT05672472N/AJan 10, 2023Jinlin University
NCT05343338N/AApr 20, 2022Jiao Tong University
NCT04973670Phase 3Oct 11, 2021Southeast University
NCT04909697Phase 4Jul 1, 2021Sichuan University
NCT00738348N/AApr 1, 2007Kochi University
NCT01170845N/AMar 1, 2007Yokohama City University
NCT00417326Phase 2Dec 1, 2006Ono Pharmaceuticals
NCT00219375Phase 4Jun 1, 2004Ono Pharmaceuticals
NCT00036062Phase 1/Phase 2 (Phase 2)Aug 1, 2001Eli Lilly
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (19)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Capital Medical UniversityAcademic/Hospital3312023
Jiao Tong UniversityAcademic/Hospital2122022
Ono PharmaceuticalsFor profit2222004
Anhui Medical UniversityAcademic/Hospital1012025
Changhai HospitalAcademic/Hospital1012025
Chinese Academy of Medical SciencesAcademic/Hospital1112024
Eli LillyFor profit1112001
Fudan UniversityAcademic/Hospital1112025
Fujian Provincial HospitalAcademic/Hospital1012025
Government of ChinaGovernment1012024
Jinlin UniversityAcademic/Hospital1112023
Kochi UniversityAcademic/Hospital1112007
Peking UniversityAcademic/Hospital1012024
Shantou UniversityAcademic/Hospital1012025
Sichuan UniversityAcademic/Hospital1112021
Southeast UniversityAcademic/Hospital1112021
The University of Hong KongAcademic/Hospital1012025
University of StrasbourgAcademic/Hospital1112026
Yokohama City UniversityAcademic/Hospital1112007
19 organizations
Page 1 / 1